» Articles » PMID: 23765535

Epithelial-mesenchymal Transition Markers in the Differential Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors

Overview
Specialty Pathology
Date 2013 Jun 15
PMID 23765535
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To elucidate the role of epithelial-mesenchymal transition markers in gastroenteropancreatic neuroendocrine tumors (GEP NETs) and the potential usefulness in their clinical management.

Methods: One hundred ten GEP NET paraffin-embedded samples were immunohistochemically analyzed for E-cadherin, N-cadherin, β-catenin, vimentin, Snail1, Snail2, Twist, and Foxc2 protein expression.

Results: The 5-year survival rate was reduced for those patients showing high Snail1 protein levels, a cytoplasmic E-cadherin pattern, reduced N-cadherin expression, and loss of E-cadherin/β-catenin adhesion complex integrity at the cell membrane. Interestingly, high β-catenin expression was useful in identifying a grade 1 NET subgroup with a favorable clinical course. Importantly, it also helped to discriminate small-cell vs large-cell grade 3 neuroendocrine carcinomas.

Conclusions: β-Catenin and N-cadherin immunohistochemical detection might be a useful tool in the differential diagnosis of small-cell vs large-cell G3 neuroendocrine carcinomas. High Snail1 and Foxc2 expression is associated with the invasion and metastatic spread of GEP NETs.

Citing Articles

Primary small rectal neuroendocrine tumor with pelvic lateral lymph nodes metastasis: A case report and review of literature.

Li L, Chen Z, Zhu D, Lv Q, Zhang T, Lai J Int J Surg Case Rep. 2025; 127:110963.

PMID: 39889652 PMC: 11834123. DOI: 10.1016/j.ijscr.2025.110963.


Development of 3D-iNET ORION: a novel, pre-clinical, three-dimensional in vitro cell model for modeling human metastatic neuroendocrine tumor of the pancreas.

Strnadel J, Valasek M, Lin G, Lin H, Tipps A, Woo S Hum Cell. 2024; 37(5):1593-1601.

PMID: 39103560 PMC: 11341600. DOI: 10.1007/s13577-024-01113-7.


CXCR4: From Signaling to Clinical Applications in Neuroendocrine Neoplasms.

Sanchis-Pascual D, Del Olmo-Garcia M, Prado-Wohlwend S, Zac-Romero C, Segura Huerta A, Hernandez-Gil J Cancers (Basel). 2024; 16(10).

PMID: 38791878 PMC: 11120359. DOI: 10.3390/cancers16101799.


Distribution of E- and N-cadherin in subgroups of non-functioning pituitary neuroendocrine tumours.

Oystese K, Casar-Borota O, Berg-Johnsen J, Berg J, Bollerslev J Endocrine. 2022; 77(1):151-159.

PMID: 35674926 PMC: 9242907. DOI: 10.1007/s12020-022-03051-6.


Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series.

Guerrera L, Suarato G, Napolitano R, Perrone A, Caputo V, Ventriglia A Healthcare (Basel). 2022; 10(4).

PMID: 35455885 PMC: 9028985. DOI: 10.3390/healthcare10040708.